Several other analysts also recently issued reports on the company. Zacks Investment Research downgraded Oxford Immunotec Global from a buy rating to a hold rating in a research note on Thursday, August 1st. BidaskClub raised Oxford Immunotec Global from a strong sell rating to a sell rating in a research note on Saturday, August 3rd. Finally, TheStreet downgraded Oxford Immunotec Global from a c- rating to a d+ rating in a research note on Monday, July 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the stock. Oxford Immunotec Global presently has an average rating of Hold and an average target price of $18.00.
Shares of OXFD opened at $14.07 on Tuesday. The company’s 50 day simple moving average is $13.41. The company has a market cap of $385.77 million, a P/E ratio of 14.94 and a beta of 0.33. Oxford Immunotec Global has a 12-month low of $11.88 and a 12-month high of $19.19. The company has a debt-to-equity ratio of 0.04, a current ratio of 12.60 and a quick ratio of 12.03.
In related news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $19.90, for a total transaction of $59,700.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.21% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Northern Trust Corp increased its stake in Oxford Immunotec Global by 0.7% in the 4th quarter. Northern Trust Corp now owns 290,723 shares of the company’s stock worth $3,715,000 after acquiring an additional 2,113 shares during the last quarter. Aperio Group LLC bought a new stake in Oxford Immunotec Global in the 2nd quarter worth approximately $42,000. JPMorgan Chase & Co. increased its stake in Oxford Immunotec Global by 3.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 94,354 shares of the company’s stock worth $1,298,000 after acquiring an additional 3,157 shares during the last quarter. Campbell & CO Investment Adviser LLC increased its stake in Oxford Immunotec Global by 15.0% in the 2nd quarter. Campbell & CO Investment Adviser LLC now owns 24,941 shares of the company’s stock worth $343,000 after acquiring an additional 3,255 shares during the last quarter. Finally, Penn Capital Management Co. Inc. increased its stake in Oxford Immunotec Global by 1.7% in the 2nd quarter. Penn Capital Management Co. Inc. now owns 271,938 shares of the company’s stock worth $3,742,000 after acquiring an additional 4,648 shares during the last quarter. 91.19% of the stock is currently owned by institutional investors.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.